On February 28, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that it has completed the localization deployment of DeepSeek and achieved full synergy with its core business, the “Thousand Mice, Ten Thousand Antibodies” program. This technological integration marks a new stage of intelligence and dataization in the early – stage R & D of antibody drugs.
Synergy and Future Prospects
The synergy between DeepSeek and the “Thousand Mice, Ten Thousand Antibodies” program will provide global pharmaceutical companies with more precise and breakthrough antibody drug R & D solutions in the future, greatly accelerating the drug development process.
Program Details and Achievements
Biocytogen launched the “Thousand Mice, Ten Thousand Antibodies” program in 2020, targeting over 1,000 potential antibody drug targets for antibody development on its self – developed RenMab, RenLite, and RenNano fully human antibody mouse platforms. To date, it has obtained over 500,000 fully human antibody sequences for more than 1,000 drug targets, covering various antibody formats such as monoclonal antibodies, bispecific antibodies, and nanobodies. These antibodies have the advantages of high affinity, low immunogenicity, and drugability. In the future, this fully human antibody molecule library will rapidly expand to the tens of millions.
Combined Advantages
Biocytogen stated in the announcement that the combination of the “Thousand Mice, Ten Thousand Antibodies” antibody library and the DeepSeek platform can provide global pharmaceutical companies with new monoclonal, bispecific, and multispecific antibody frameworks. These frameworks have high affinity, low immunogenicity, and excellent drugability. With the help of the DeepSeek platform, global pharmaceutical companies can quickly screen out target antibody molecules with high drug potential from the tens of millions of antibody molecules in the “Thousand Mice, Ten Thousand Antibodies” library.
DeepSeek’s Capabilities
DeepSeek can also design multispecific antibodies with specific functions, such as bispecific and multispecific antibodies, by simulating molecular interactions and obtaining molecular frameworks from the vast antibody library of “Thousand Mice, Ten Thousand Antibodies”. This enables the rapid development of innovative antibody drugs for various diseases, greatly accelerating the drug development process and meeting unmet clinical needs.-Fineline Info & Tech
Leave a Reply